Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-target Effects with Reduced Off-tumor Toxicity for Use in Immuno-Oncology.
Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-target Effects with Reduced Off-tumor Toxicity for Use in Immuno-Oncology. Clin Cancer Res. 2019 Oct 10;: Authors: Autio KA, Boni V, Humphrey RW, Naing A Abstract The deep and durable antitumor effects of antibody-based immunotherapies such as immune checkpoint inhibitors (ICIs) have revolutionized oncology and transformed the therapeutic landscape for many cancers. Several anti-programmed death receptor 1 and anti-programmed death receptor ligand 1 antibodies have been approved for use in advanced solid tumors, including melanoma, non-small cell lung cancer (NSCLC), bladder cancer, and other cancers. ICIs are under development across many tumor types and preliminary results are compelling. However, ICIs have been associated with severe immune-related adverse events (irAEs), including rash, diarrhea, colitis, hypophysitis, hepatotoxicity, and hypothyroidism, which in some cases lead to high morbidity, are potentially life-threatening, and limit the duration of treatment. The incidence of severe irAEs increases further when programmed cell death-1 and programmed cell death ligand-1 inhibitors are combined with anti-CTLA-4 and/or other multi-drug regimens. Probody therapeutics, a new class of recombinant, proteolytically activated antibody prodrugs are in early development and are designed to exploit the hallmark of dysregulation of tumor protease activity to deliver their therapeu...
DNA changes in a common type of breast cancer cell may be linked to hormone therapy resistance, according to a study published inNature Communications.Science Daily
We have vacancies for the Editor-in-Chief positions on the Editorial Boards of Endocrine Connections and Endocrine-Related Cancer.Endocrine Connections is jointly owned by the Society for Endocrinology and the European Society of Endocrinology. It is an open access journal offering authors the highest possible visibility for their work and stimulating cross-discipline collaboration. Read the full job description.Endocrine-Related Cancer is the official flagship journal of the Society for Endocrinology and is endorsed by the European Society of Endocrinology, Endocrine Society of Australia...
Conclusion The current level of awareness for clinical trials of cancer patients in our hospital was relatively low, even in patients who had atte nded clinical trials before. It’s necessary to improve patients’ awareness of clinical trial by promoting harmony relationship between patients and doctors, as well as by enhancing related propagation. Strengthening the adequacy and efficacy of informed consent in clinical trials also needs to b e achieved in the future. DOI: 10.3779/j.issn.1009-3419.2020.01.02
Conclusion T4 stage patients had worse survival in N2 group. To get a more precisely stratification, skip metastasis and number of involved lymph node stations should be considered in future N stage classification. DOI: 10.3779/j.issn.1009-3419.2020.01.03
Conclusion The expression of TRIM59 is closely related to the prognosis of NSCLC patients, and it is an independent risk factor for NSCLC patients. DOI: 10.3779/j.issn.1009-3419.2020.01.04
This study mainly explores the relationship between the ASPM expression of lung adenocarcinoma and the development and prognosis of lung cancer. The aim of this study was to investigate the relationship between the expression of abnormal spindle-like microcephaly-associated protein (ASPM) in lung adenocarcinoma and the development and prognosis in lung cancer. Methods A total of 90 cases of lung adenocarcinoma tissue specimens and 90 cases of benign pulmonary lesions were collected, the expression of ASPM was detected by immunohistochemical technique, and the expression of ASPM in 12 pairs of tissues was detected by real-t...
Conclusion It was safety to discontinued oral antiplatelet agents before operation, with no MACE and death in perioperative period. DOI: 10.3779/j.issn.1009-3419.2020.01.06
Conclusion The acceptance of clinical trials in cancer patients in our hospital is generally high, especially in patients who had a history of trial participation. It ’s of substantial significance to give full play to the role of doctors in improving the acceptance of clinical trials of cancer patients in China. DOI: 10.3779/j.issn.1009-3419.2020.01.07
Conclusion This study optimizes the procedure of port-only artificial pneumothorax robot-assisted lobectomy in order to serve lung cancer patients better. DOI: 10.3779/j.issn.1009-3419.2020.01.08